

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM348320

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT		
NATURE OF CONVEYANCE:	Corrective Assignment to correct the the number of assignors, applications and registrations that are included in the merger previously recorded on Reel 005574 Frame 0569. Assignor(s) hereby confirms the Merger.		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Vyrix Pharmaceuticals, Inc.		04/16/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Rosewind Corporation		
Street Address:	373 Inverness Parkway, Suite 200		
City:	Englewood		
State/Country:	COLORADO		
Postal Code:	80112		
Entity Type:	CORPORATION: COLORADO		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	85794283	ZERTANE	
Serial Number:	85874868	POPE	
CORRESPONDENCE DATA			
Fax Number:	3038630223		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	303-863-9700		
Email:	phirschman@sheridanross.com		
Correspondent Name:	Miriam D. Trudell & Pamela N. Hirschman		
Address Line 1:	Sheridan Ross P.C.		
Address Line 2:	1560 Broadway, Suite 1200		
Address Line 4:	Denver, COLORADO 80202		
ATTORNEY DOCKET NUMBER:	4172-113		
NAME OF SUBMITTER:	Pamela N. Hirschman		
SIGNATURE:	/Pamela N. Hirschman/		
DATE SIGNED:	07/16/2015		
Total Attachments: 6			
source=LUOXIS DIAGNOSTICS INC DE - CERTIFICATE OF OWNERSHIP (2)#page1.tif			

CH \$65.00 85794283

source=LUOXIS DIAGNOSTICS INC DE - CERTIFICATE OF OWNERSHIP (2)#page2.tif
source=LUOXIS DIAGNOSTICS INC DE - CERTIFICATE OF OWNERSHIP (2)#page3.tif
source=LUOXIS DIAGNOSTICS INC DE - CERTIFICATE OF OWNERSHIP (2)#page4.tif
source=LUOXIS DIAGNOSTICS INC DE - CERTIFICATE OF OWNERSHIP (2)#page5.tif
source=Original CoverSheet#page1.tif

Delaware

PAGE 1

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:


"LUOXIS DIAGNOSTICS, INC.", A DELAWARE CORPORATION,
"VYRIX PHARMACEUTICALS, INC.", A DELAWARE CORPORATION,
WITH AND INTO "ROSEWIND CORPORATION" UNDER THE NAME OF "ROSEWIND CORPORATION", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF COLORADO, AS RECEIVED AND FILED IN THIS OFFICE THE SIXTEENTH DAY OF APRIL, A.D. 2015, AT 2:24 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

5730229 8100M

150520689




Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 2297047

DATE: 04-16-15

You may verify this certificate online
at corp.delaware.gov/authver.shtml

TRADEMARK
REEL: 005578 FRAME: 0600

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

VYRIX PHARMACEUTICALS, INC., a Delaware Corporation

and

LUOXIS DIAGNOSTICS, INC., a Delaware Corporation

WITH AND INTO

ROSEWIND CORPORATION, a Colorado Corporation

April 16, 2015

Pursuant to Section 253 of the Delaware General Corporation Law (the "DGCL"), Rosewind Corporation, a Colorado corporation (the "Corporation"), does hereby certify to the following information relating to the mergers (the "Mergers") of Luoxis Diagnostics, Inc., a Delaware corporation ("Luoxis"), and Vyrix Pharmaceuticals, Inc., a Delaware corporation ("Vyrix"), with and into the Corporation, with the Corporation remaining as the surviving corporation:

1. Both Luoxis and Vyrix are incorporated pursuant to the DGCL, the provisions of which permit a merger of a corporation of that jurisdiction with a corporation of another jurisdiction.
2. The Corporation is incorporated pursuant to the Colorado Business Corporation Act (the "CBCA"), the provisions of which permit a merger of a corporation of that jurisdiction with a corporation of another jurisdiction.
3. The Corporation is the owner of all of the issued and outstanding shares of capital stock of each of Luoxis and Vyrix that, absent Section 253 of the DGCL, would be entitled to vote on the Merger.
4. The Board of Directors of the Corporation, by resolutions duly adopted by unanimous written consent on March 24, 2015, determined to merge each of Luoxis and Vyrix with and into the Corporation pursuant to Section 253 of the DGCL, which resolutions are as follows:

WHEREAS: The Corporation owns all of the issued and outstanding shares of each class of capital stock of each of Luoxis and Vyrix.

WHEREAS: It is deemed advisable and in the best interest of the Corporation that the Corporation merge each of Luoxis and Vyrix with and into the Corporation.

NOW, THEREFORE, BE IT:

RESOLVED: That, as a result of the Mergers, the Corporation shall be the surviving corporation possessed of all the estate, property, rights, privileged and franchises of each of Luoxis and Vyrix, and the Corporation shall assume all of the liabilities and obligations of each of Luoxis and Vyrix pursuant to and in the manner prescribed by Section 253 of the DGCL.

RESOLVED: The separate existence of each of Luoxis and Vyrix shall cease as soon as the Mergers shall become effective, and the Corporation shall continue as the surviving corporation.

RESOLVED: That the proper officers of the Company be, and each of them acting singly hereby is, authorized, empowered and directed in the name and on behalf of the Corporation, to execute and file or cause to be filed and/or recorded the documents prescribed by the (i) laws of the State of Delaware, including, without limitation, an appropriate Certificate of Ownership and Merger (the "Certificate of Merger") embodying these resolutions as required by Section 253 of the DGCL and any and all additional documents and information required to be filed therewith, filed with the Secretary of State of the State of Delaware, (ii) by the laws of the State of Colorado, and by the laws of any other appropriate jurisdiction and will cause to be performed all necessary acts within the jurisdiction of organization of Luoxis, Vyrix and of the Corporation and in any other appropriate jurisdiction.

RESOLVED: That the Mergers shall be effective upon the filing of the Certificate of Merger with the Secretary of the State of Delaware.

RESOLVED: That, upon the proposed Mergers becoming effective, each outstanding share of capital stock of each of Luoxis and Vyrix owned of record by the Corporation shall cease to be outstanding, without any payment being made in respect thereof.

5. The Corporation shall be the surviving corporation of the Mergers.
6. The Certificate of Incorporation of the Corporation, as in effect immediately prior to the Merger, shall be the Certificate of Incorporation of the surviving corporation.
7. This Certificate of Ownership and Merger and the Mergers shall become effective upon the filing of such Certificate of Ownership and Merger with the Delaware Secretary of State.

8. The Corporation agrees that it may be served with process in the State of Delaware in any proceeding for enforcement of any obligation of any constituent corporation of Delaware, as well as the enforcement of any obligation of the Corporation arising from the Merger, and irrevocably appoints the Secretary of State of Delaware as its agent to accept services of process in any such suit or proceeding. The Secretary of State shall mail a copy of any such process to the Corporation at:

Rosewind Corporation
c/o Ampio Pharmaceuticals, Inc.
373 Inverness Parkway, Suite 200
Englewood, Colorado 80112
Attention: Chief Financial Officer
Email: ggould@ampiopharma.com

9. The Mergers have been adopted, approved, certified, executed and acknowledged by the Corporation pursuant to and in accordance with the CBCA.

The remainder of this page is intentionally left blank

IN WITNESS WHEREOF, the undersigned has caused this Certificate of Ownership and Merger to be duly executed as of the date first written above.

ROSEWIND CORPORATION

By: /s/ James B. Wiegand

Name: James B. Wiegand

Date: President

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM347516

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	MERGER		
EFFECTIVE DATE:	04/16/2015		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Luoxis Diagnostics, Inc.		04/16/2015	CORPORATION: DELAWARE
Vyrix Pharmaceuticals, Inc.		04/16/2015	CORPORATION: DELAWARE
Rosewind Corporation		04/16/2015	CORPORATION: COLORADO
RECEIVING PARTY DATA			
Name:	Rosewind Corporation		
Street Address:	373 Inverness Parkway, Suite 200		
City:	Englewood		
State/Country:	COLORADO		
Postal Code:	80112		
Entity Type:	CORPORATION: COLORADO		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	4614571	LUOXIS DIAGNOSTICS	
Registration Number:	4629651	LUOXIS	
Registration Number:	4629575	REDOXSYS	
Serial Number:	85874868	POPE	
Serial Number:	85794283	ZERTANE	
CORRESPONDENCE DATA			
Fax Number:	3038630223		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	303-863-9700		
Email:	phirschman@sheridanross.com		
Correspondent Name:	Miriam D. Trudell & Pamela N. Hirschman		
Address Line 1:	Sheridan Ross P.C.		
Address Line 2:	1560 Broadway, Suite 1200		
Address Line 4:	Denver, COLORADO 80202		
ATTORNEY DOCKET NUMBER:	5753-31		
NAME OF SUBMITTER:	Pamela N. Hirschman		

CH \$140.00 4614571